Skip to main content
main-content

Cardiovascular outcomes

News

10-16-2018 | Metabolic surgery | medwireNews | News

Marked reduction in vascular events in diabetes patients after bariatric surgery

An observational study published in JAMA demonstrates a substantial reduction in the risk for hard cardiovascular endpoints in obese patients with type 2 diabetes who have undergone bariatric surgery.

10-05-2018 | Linagliptin | EASD 2018 | News

Favorable long-term cardiovascular safety profile of linagliptin in type 2 diabetes

Findings from the CARMELINA trial suggest that the dipeptidyl peptidase-4 inhibitor linagliptin has a similar cardiovascular safety profile to placebo when added to standard care in high-risk type 2 diabetes patients.

10-02-2018 | Albiglutide | EASD 2018 | News

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

Read more

Opinion

11-22-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

11-13-2017 | Specific populations | Interview | Video

Women and diabetes - our right to a healthy future

Editorial Board member Lori Berard addresses 2017's World Diabetes Day theme, providing her insights on the key considerations for managing diabetes in women in this interview with Medicine Matters diabetes (9:51).

10-23-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Glucagon-like peptide-1 receptor agonist use in acute myocardial infarction

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.

In depth

10-17-2017 | GLP-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

08-22-2017 | Canagliflozin | Podcast | Audio

Dissecting the CANVAS trial

Listen to CANVAS investigators Carol Wysham and Lori Berard discussing the efficacy and safety findings of the trials (11:17).

Journal articles and book chapters

08-31-2018 | GLP-1 agonists | Review | Article

Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes

Bahtiyar G, Pujals-Kury J, Sacerdote A. Curr Diab Rep 2018; 18: 92. doi: 10.1007/s11892-018-1043-z

08-30-2018 | Obesity | Review | Article

The impact of childhood and adolescent obesity on cardiovascular risk in adulthood: A systematic review

Sommer A, Twig G. Curr Diab Rep 2018; 18: 91. doi: 10.1007/s11892-018-1062-9

07-23-2018 | SGLT2 inhibitors | Review | Article

SGLT2 inhibitors in type 2 diabetes management: Key evidence and implications for clinical practice

Wilding J et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0471-8

image credits